The role of gold nanoparticles' aspect ratio in plasmon-enhanced luminescence and the singlet oxygen generation rate of Mo6 clusters.

Here we present a study on the effect of the aspect ratio (AR) of gold nanoparticles on the emission intensity and singlet oxygen production rate of hexamolybdenum cluster-doped silica particles. It was shown that these parameters can be enhanced gradually up to 6.7- and 13-fold with the AR.

Synergetic Effect of Mo6 Clusters and Gold Nanoparticles on the Photophysical Properties of Both Components.

Photodynamic and photothermal therapies (PDT, and PTT, respectively) are promising candidates for multimodal anticancer therapies (i.e., combinations of therapies), since their action is based on mechanisms that generally cannot be resisted by cancer cells, that is, generation of highly oxidizing oxygen species and high temperature, respectively. Herein, hybrid materials that combine octahedral molybdenum clusters as potential PDT agents and plasmonic spherical gold nanoparticles (AuNPs) as PTT agents are reported. Partial overlap of the photoemission spectrum of the cluster and the surface plasmon resonance band of the AuNPs facilitates energy transfer between the photoactive components, which resulted in synergetic enhancement of their photophysical properties. Specifically, by careful selection of the spacing between the cluster and the gold nanoparticle, a significant increase in luminescence and photosensitizing properties of the cluster was achieved in comparison with similar, but gold-free, particles. On the other hand, the cluster complex facilitated energy conversion to heat by gold particles and hence increased the heating rate under laser irradiation.

Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers.

Monoclonal antibodies (mAb) demonstrate great potential as immunotherapy agents for the treatment of diseases such as cancer as well as tagging for the targeted delivery of multicomponent therapeutic or diagnostic systems. Nevertheless, the large physical size, poor stability of mAbs and abnormal allergic reactions still remain the main issues affecting their generalised use. Single-domain antibodies (sdAb) are seen as the next generation of antibody derived therapeutics and diagnostics. This work presents the optimised production method for HER2-specific sdAb C7b, which led to an ∼11-fold increase in protein yield. In addition, the in vitro and in vivo efficiencies of the targeted delivery of a model nanoparticle cargo (50 nm silica particles doped with Mo6 phosphorescent clusters) conjugated to C7b against those conjugated to HER2-specific trastuzumab is benchmarked. Specifically, this paper demonstrates the significantly higher rate of accumulation in and excretion from xenograft cancer tissue of nanoparticles with C7b, which is of particular importance for diagnostics, i.e. delivery of imaging agents.